|
"shao yu yun"的相關文件
顯示項目 56-65 / 94 (共10頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2014 |
The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu Yun; Hsu, Chiun; Chang, Wen-Fang; Chang, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 楊志新; 邵幼雲; 賴美淑; 鄭安理; 許駿; 賴秋伶 |
| 國立臺灣大學 |
2014 |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
|
Shao, Yu-Yun; Ho, Ming-Chih; Cheng, Ann-Lii; Hsu, Chih-Hung; 邵幼雲; 鄭安理; 徐志宏; 何明志 |
| 國立臺灣大學 |
2014 |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao, Yu-Yun; Wu, Chih-Horng; Lu, Li-Chun; Chan, Soa-Yu; Ma, Yu-Yi; Yen, Feng-Chu; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 吳志宏; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2014 |
Clinical Characteristics of Advanced Hepatocellular Carcinoma Patients with Prolonged Survival in the Era of Anti-angiogenic Targeted-therapy
|
Lu, Li-Chun; Shao, Yu-Yun; Chan, Soa-Yu; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 呂理駿 |
| 國立臺灣大學 |
2014 |
High serum transforming growth factor beta 1 levels associated with poor survivals in patients with advanced hepatocellular carcinoma
|
Lin, Tzu-Hsuan; Shao, Yu-Yun; Chan, Soa-Yu; Huang, Chung-Yi; Cheng, Ann-Lii; Hsu, Chih-Hung; 邵幼雲; 黃昭源; 鄭安理; 徐志宏 |
| 國立成功大學 |
2013 |
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
|
Hsu, Chih-Hung; Kang, Yoon Koo; Yang, Tsai-Shen; Shun, Chia-Tung; Shao, Yu-Yun; Su, Wu-Chou; Sandoval-Tan, Jennifer; Chiou, Tzeon-Jye; Jin, Kate; Hsu, Chiun; Cheng, Ann-Lii |
| 國立臺灣大學 |
2013 |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Lu, Li-Chun; Shao, Yu-Yun; Kuo, Raymond N. C.; Lin, Zhong-Zhe; Yeh, Yi-Chun; Shau, Wen-Yi; Hsu, Chih-Hung; Cheng, Ann-Lii; Lai, Mei-Shu; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 郭年真; 呂理駿 |
| 國立臺灣大學 |
2013 |
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
|
Hsu, Chih-Hung; Kang, Yoon Koo; Yang, Tsai-Shen; Shun, Chia-Tung; Shao, Yu-Yun; Su, Wu-Chou; Sandoval-Tan, Jennifer; Chiou, Tzeon-Jye; Jin, Kate; Hsu, Chiun; Cheng, Ann-Lii; 邵幼雲; 鄭安理; 徐志宏; 許駿; 孫家棟 |
| 國立臺灣大學 |
2013 |
The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
|
Shao, Yu-Yun; Chang, Yung-Lin; Huang, Chung-Yi; Hsu, Chih-Hung; Cheng, Ann-Lii; 邵幼雲; 黃昭源; 鄭安理; 徐志宏 |
| 國立臺灣大學 |
2013 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
Shao, Yu-Yun; Shau, Wen-Yi; Lin, Zhong-Zhe; Chen, Ho-Min; Kuo, Raymond; Yang, James Chih-Hsin; Lai, Mei-Shu; 楊志新; 邵幼雲; 賴美淑; 林宗哲 |
顯示項目 56-65 / 94 (共10頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
